Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA’s approval of Roche / Genentech’s Tecentriq (2019) and AstraZeneca’s Imfinzi (2020); both PD-L1 inhibitors are prescribed in combination with chemotherapy. The FDA approvals of PharmaMar / Jazz Pharmaceuticals’ Zepzelca and G1 Therapeutics’ Cosela have also expanded the treatment options for patients with extensive-stage SCLC. This content will explore U.S. physicians’ prescribing behavior when treating SCLC.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 medical oncologists in the United States fielded in June 2021
Key drugs: Cosela, Imfinzi, Tecentriq, Zepzelca